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Abstract 
Activation of the β2-adrenoceptor (β2-AR) elicits an endothelial nitric oxide synthase 
(eNOS)-dependent relaxation in mouse pulmonary artery, which, contrary to the muscarinic 
receptor-dependent relaxation, is preserved in hypoxic pulmonary arterial hypertension. We 
therefore characterized the signaling pathways underlying the β2-AR-mediated eNOS 
activation, with special focus on Gi/o proteins, protein kinases and caveolae. Functional 
studies (for evaluation of vasorelaxant responses), Western blots (for assessment of eNOS and 
caveolin-1 phosphorylations) and transmission electron microscopy (for visualization of 
caveolae) were conducted in pulmonary arteries from wild-type or caveolin-1 knockout mice. 
In wild-type isolated arteries, relaxation to the selective β2-AR agonist procaterol was reduced 
by inhibitors of Gi/o proteins (pertussis toxin, PTX), phosphatidylinositol 3-kinase (PI3K; 
wortmannin or LY 294002), Akt (Akt inhibitor X) and Src-kinase (PP2) and by cholesterol 
depletion (using methyl-β-cyclodextrin). Procaterol induced eNOS phosphorylation at Ser1177, 
which was prevented by PTX, PP2 or Akt inhibitor, as well as caveolin-1 phosphorylation at 
Tyr14, which was decreased by PTX or PP2. Caveolin-1 gene deletion resulted in endothelial 
caveolae disruption in mouse pulmonary artery and in potentiation of procaterol-induced 
relaxation. Unlike procaterol, acetylcholine-induced relaxation was unaffected by PTX, 
methyl-β-cyclodextrin or caveolin-1 gene deletion. To conclude, the mouse pulmonary 
endothelial β2-AR is coupled to a Gi/o-Src kinase-PI3K/Akt pathway to promote eNOS 
phosphorylation at Ser1177 leading to a NO-dependent vasorelaxation, and caveolin-1 exerts a 
negative control on this response, which is removed by its phosphorylation at Tyr14 through a 
Gi/o-Src kinase pathway. Since pulmonary β2-AR- and muscarinic receptor-mediated 
relaxations differentiate in their respective signaling pathways leading to eNOS activation and 
susceptibilities during hypoxia-induced pulmonary arterial hypertension, mechanisms 
underlying eNOS activation might be key determinants of pulmonary endothelial dysfunction. 
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1. Introduction 
 
Nitric oxide (NO), produced by the endothelial NO synthase (eNOS), is a major 
vasculoprotective agent owing to its vasodilator, anti-aggregant, anti-oxidant and anti-
proliferative properties [1]. Endothelial dysfunction, and particularly an impaired endothelial 
NO production and/or availability, plays a key role in many cardiovascular risk factors and 
diseases, including pulmonary arterial hypertension [2]. Pulmonary arterial hypertension is a 
severe disease, leading to right ventricular hypertrophy followed by right ventricular failure 
and ultimately death. The increase in pulmonary arterial resistances is the consequence of 
both structural remodelling and alterations of vasomotor responses, related to the imbalance 
between vasodilatator/antiproliferative and vasoconstrictor/proliferative factors [3]. 
Restoration of NO production and/or availability in pulmonary arteries appears to be an 
interesting therapeutic approach to treat this disease.  
 
As in other cardiovascular diseases, endothelial dysfunction in models of pulmonary 
arterial hypertension is established when pulmonary arteries exhibit a decrease in the relaxant 
response to acetylcholine, the reference endothelium-dependent vasodilator, acting through 
the activation of endothelial muscarinic receptors coupled to NO production [4,5]. In a mouse 
model of chronic hypoxia-induced pulmonary arterial hypertension, we have shown that the 
relaxant response induced by the β2-AR stimulation, which is also endothelium- and eNOS-
dependent, is preserved, whereas the relaxant response to acetylcholine is decreased [5,6]. 
The preservation of this pulmonary endothelium-dependent β2-adrenergic vasorelaxation 
highlights the potential interest of the β2-AR as a therapeutic target in pulmonary arterial 
hypertension and suggests that the mechanisms underlying eNOS activation are determinant 
for expression of endothelial dysfunction in pulmonary arteries. Although β2-ARs have been 
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described as endothelial β-ARs associated with a NO-dependent relaxant response in some 
systemic vascular beds [7-9], there is limited information about the molecular mechanisms 
underlying the β2-adrenergic-mediated activation of eNOS. 
 
The regulation of eNOS activity involves complex molecular mechanisms, including not 
only the calcium/calmodulin-dependent pathway, but also posttranslational mechanisms 
especially through modifications of eNOS phosphorylation and eNOS-protein interactions 
[10,11]. In particular, caveolin-1, a major protein of endothelial caveolae, interacts with the 
inactive state of eNOS and the dissociation of this complex increases eNOS activity [12,13]. 
Whereas in mouse pulmonary arteries muscarinic-dependent activation of eNOS involves the 
M3 subtype [14], which is coupled to a Gq/phospholipase C pathway and subsequent increase 
in cytosolic calcium concentration in endothelial cells, it is worth noting that the coupling 
mechanism between β2-AR and eNOS remains unknown in these arteries, except that it is 
independent of a cAMP/cAMP-dependent protein kinase (PKA) pathway [6], suggesting that 
Gs proteins are not recruited. 
 
The aim of this study was therefore to identify the components of the signaling pathway 
involved in eNOS activation elicited by endothelial β2-AR stimulation and responsible for the 
β2-AR-mediated relaxation in the mouse pulmonary artery. Specifically, the following issues 
were addressed: (i) to evaluate the role of Gi/o proteins in the β2-adrenergic relaxant response, 
as β2-ARs are known to couple not only to Gs but also to Gi/o proteins, in several tissues 
including cardiovascular ones [15,16]; (ii) to determine the effect of β2-AR stimulation on 
eNOS phosphorylation, at the key activating Ser1177 residue of eNOS [17,18], and identify the 
protein kinases involved in eNOS phosphorylation; (iii) to investigate the role of caveolae and 
caveolin-1 in the mouse pulmonary β2-adrenergic relaxant response. 
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The contribution of these different signaling molecules to the pulmonary endothelial β2-
AR-mediated activation of eNOS was investigated by using pharmacological tools and a 
genetic approach with caveolin-1 knockout mice (Cav-1 KO). In some experiments, the β2-
adrenergic response was compared to the reference muscarinic relaxation which is also NO-
dependent [5]. 
 
 
 
 
 
 
 8
2. Material and Methods 
 
The investigation is in accordance with the EC Directive 86/609/EEC on the ″Protection of 
animals used for experimental and other scientific purposes″. Agreement (number A 33409) 
was obtained from French authorities. 
 
2.1. Reagents and antibodies 
In the absence of indication, drugs were obtained from Sigma-Aldrich (St. Quentin, 
Fallavier, France). Procaterol was from Tocris Bioscience (Bristol, UK). Pertussis toxin 
(PTX) and all kinases inhibitors (Akt inhibitor X, compound C, LY 294002, PD 98059, PP2, 
SB 203580, SP 600125, U0126, wortmannin) were from Calbiochem (Merck Chemicals Ltd, 
Nottingham, UK). Prostaglandin F2α (PGF2α) (dinoprost tromethamine, Dinoprost) was 
obtained from Pfizer (Paris, France), the phosphatase inhibitor cocktail from Thermo Fisher 
Scientific (Cergy Pontoise, France), Dulbecco’s Modified Eagle’s Medium (DMEM) from 
Gibco (Invitrogen, Cergy Pontoise, France) and NuPAGE® from Invitrogen. 
Pharmacological agents (PTX, agonists receptors, kinases inhibitors and methyl-β-
cyclodextrin) were prepared in distilled water except compound C, LY 294002, PD 98059, 
PP2, SB 203580, SP 600125, U0126 and wortmannin which were prepared in Dimethyl 
Sulfoxide (DMSO). Drugs concentrations were chosen according to their pharmacological 
properties (affinity and selectivity) described in the litterature. 
Primary antibodies were anti-eNOS (monoclonal, BD Transduction Laboratories, San Jose, 
CA, USA), anti-phospho-eNOS (Ser1177) (polyclonal; Cell Signaling Technology, Beverly, 
MA, USA), anti-caveolin-1 (polyclonal; BD Transduction Laboratories), anti-phospho-
caveolin-1 (Tyr14) (polyclonal; Cell Signaling Technology), anti-β-actin (monoclonal; Sigma-
Aldrich). Horseradish peroxidase-conjugated secondary antibodies were obtained from 
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Jackson Immunoresearch Laboratories (Suffolk, UK; for eNOS and phospho-eNOS detection) 
or Thermo Fisher Scientific (for caveolin-1 and β-actin detection).  
 
2.2. Animals and tissues 
Male C57BL6 mice (8-12 weeks old) were purchased from Elevage Janvier (Le Genest St 
Isle, France). Some experiments were conducted in male Cav-1 KO mice and their wild-type 
littermates (WT, C57BL6-background) (5-6 months old; a gift from Dr. C. Dessy, Unit of 
Pharmacology and Therapeutics, Université Catholique de Louvain, Brussels, Belgium). 
Left and right branches of the extralobar pulmonary artery were removed and cleaned of 
adventitial tissue [5]. These vessels were immediately used for functional and biochemical 
studies, except those used for the evaluation of the role of Gi/o proteins, which were incubated 
in DMEM in the absence or presence of 400 ng/ml PTX for 12 hours at 37°C in a humidified 
atmosphere (95% air / 5% carbon dioxide). 
 
2.3. Vascular reactivity studies 
Segments of pulmonary arteries were mounted in a wire myograph (Multi Myograph 
System, model 610M, J.P. Trading, Aarhus, Denmark) to measure isometric tension, as 
previously described [5,6]. Relaxant effects of 10 µM acetylcholine and 0.1 µM procaterol (in 
the presence of the α-adrenoceptor antagonist phentolamine, 10 µM) were studied in the same 
artery, after submaximal pre-contraction with PGF2α. To characterize the signaling pathway 
involved in vasorelaxation, arteries were pretreated before addition of PGF2α in the absence or 
presence of the cholesterol-depleting agent (1 mM methyl-β-cyclodextrin) or enzyme 
inhibitors [for phosphatidylinositol 3-kinase (PI3K; 10 µM LY 294002 or 0.1 µM 
wortmannin), Akt (5 µM Akt inhibitor X), Src-kinase (10 µM PP2), mitogen-activated protein 
kinases (MAPK) pathway (20 µM PD 98059, 10 µM UO126, 5 µM SB 203580 or 10 µM SP 
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600125), AMP-activated protein kinase (AMPK; 2 µM compound C), or NOS (300 µM Nω-
nitro-L-arginine methylester, L-NAME)]. In experiments performed in the presence of 
pharmacological agents diluted in DMSO, control arteries were incubated in the presence of 
the equivalent concentration of DMSO. 
Relaxant effects induced by procaterol and acetylcholine are expressed as percentage of 
relaxation of the tone induced by PGF2α. The area of the relaxant effect, measured over 15 
min, was evaluated with Origin 6 software (Microcal Inc, Piscataway, NJ, USA) and reported 
to the amplitude of contraction induced by PGF2α.    
 
2.4. Western blot 
To evaluate the effect of β2-AR stimulation on phosphorylation of eNOS and caveolin-1, 
pulmonary arteries were placed in the myograph chambers. After pretreatment in the absence 
or presence of kinase inhibitors (as described in vascular reactivity studies), arteries were 
incubated with 10 µM PGF2α and 10 µM phentolamine for 30 min, before addition of solvent 
or procaterol (0.1 µM) for 30 sec or 5 min. The arteries were then quickly frozen in liquid 
nitrogen, and stored at -80°C. To evaluate the expression of caveolin-1, pulmonary arteries 
isolated from Cav-1 KO and WT mice were frozen immediately after their removal from 
animals. 
Arteries were homogenized in cold lysis buffer [containing: 1% sodium dodecyl sulfate 
(SDS), 10-2 M Tris-HCl (pH 7.4), 5 µg/ml aprotinin, 2.5 µg/ml leupeptin and phosphatase 
inhibitor cocktail] for 45 min on ice followed by brief sonication. Tissue lysates were 
centrifuged (15 000 g for 10 min at 4°C) and the supernatant was resuspended in the loading 
buffer (NuPAGE® with 5% β-mercaptoethanol). Proteins were resolved by electrophoresis 
(Mini Gel Protean III System, Bio-Rad Laboratories, Hercules, CA, USA) in a 10% Tris-
Glycine gel and transferred on Hybond ECL membranes (Amersham Biosciences, 
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Piscataway, NJ, USA) for 45 minutes at 100 V (Minitrans-blot Cell, Bio-Rad Laboratories). 
Membranes were blocked overnight at 4°C. After incubation with the appropriate primary 
antibody, membranes were then incubated with the appropriate horseradish peroxidase-
conjugated secondary antibody. Proteins were visualized using a chemiluminescence 
detection kit (Lumi-Light, Roche Diagnostics, Meylan, France).   
 
2.5. Transmission Electronic Microscope Examination 
Pulmonary arteries isolated from Cav-1 KO and WT mice were fixed with 2.5% 
glutaraldehyde in 0.1 M phosphate buffer for 2 hours at 4°C, post-fixed in 1% osmium 
tetroxide in 0.1 M phosphate buffer for 1 hour at room temperature, dehydrated through a 
series of graded ethanol and propylene oxide, and embedded in a mixture of propylene oxide 
and Epoxy resin (v/v) for 2 hours and then in 100% Epon resin. The resin was polymerized at 
60°C for 48 hours. The samples were sectioned using a diamond knife on an ultra-microtome 
(Ultracut-E, Leica Microsystems). Thin sections (70 nm) were picked up on copper grids and 
then stained with uranyl acetate and lead citrate. The grids were examined with a transmission 
electron microscope at 120kV (Tecnai 12, FEI).  
 
2.6. Statistical analysis 
Data are given as mean ± S.E.M. of n experiments (n: number of mice). Different 
parameters were compared using Student’s t-test for paired or unpaired data, where 
appropriate. A value of P<0.05 was considered significant. 
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3. Results 
 
3.1. Role of Gi/o proteins in the β2-AR-mediated relaxant response in mouse pulmonary 
artery   
In a previous study, we have shown that in mouse pulmonary artery precontracted by 
PGF2α, 0.1 µM procaterol (in the presence of phentolamine) induces a relaxation which is 
exclusively due to the endothelial β2-AR, eNOS and soluble guanylyl-cyclase stimulation [6]. 
As shown in Figure 1, a pretreatment of arteries with PTX, a Gi/o protein inhibitor, 
significantly reduced the relaxation to procaterol without affecting the relaxation elicited by 
acetylcholine, the muscarinic agonist. This suggests that the β2-AR-mediated relaxant 
response involves activity of Gi/o proteins. 
 
3.2. Role of eNOS phosphorylation in the β2-AR-mediated relaxant response in mouse 
pulmonary artery   
The phosphorylation status of eNOS is a critical determinant of its activity. As numerous 
kinases (including PI3K/Akt, PKA, AMPK, MAPK cascade, Src-kinase) may either directly 
or indirectly contribute to eNOS activation depending on the stimulus [10,11], we evaluated 
the effect of pharmacological inhibitors of these different pathways on the pulmonary β2-AR-
mediated relaxant response. Two PI3K inhibitors (wortmannin or LY 294002), the Akt 
inhibitor X and the Src-kinase inhibitor PP2 significantly decreased the amplitude of 
relaxation induced by procaterol in mice pulmonary arteries (Fig. 2A, B, D). The concomitant 
application of LY 294002 and PP2 further decreased the response to procaterol (76% 
inhibition with LY 294002 + PP2 compared 41% and 46% inhibition with LY 294002 and 
PP2, respectively; P<0.05). By contrast, the inhibitors of ERK1/2 pathway (UO126 or PD 
98059), p38-MAPK (SB 203580), c-Jun N-terminal kinase (JNK; SP 600125) and AMPK 
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(compound C) have no effect on this procaterol-mediated relaxant response (Fig. 2A, C, E). 
This suggests that in mouse pulmonary arteries, PI3K/Akt and Src-kinase, but not ERK1/2, 
p38-MAPK, JNK or AMPK, pathways participate in the β2-adrenergic relaxation. 
The PI3K/Akt pathway is known to directly phosphorylate the key Ser1177 residue of 
eNOS, leading to its activation [17,18], whereas Src-kinase has been reported to act upstream 
of PI3K/Akt [19,20]. We then determined the effect of 0.1 µM procaterol (in the presence of 
PGF2α to mimic the experimental conditions of vascular reactivity studies) on eNOS 
phosphorylation at Ser1177 in mouse pulmonary arteries. As shown in Figure 3A, stimulation 
of mouse pulmonary arteries with procaterol increased the phosphorylation of eNOS at 
Ser1177. This effect was observed after a 30 sec-incubation and further increased after 5 min to 
become statistically significant. Both Akt inhibitor X and PP2 abolished the effect of 
procaterol on the phosphorylation of eNOS at Ser1177 (Fig. 3B). In PTX-pretreated arteries, 
procaterol failed to modify eNOS phosphorylation at Ser1177 (Fig. 3B). 
 
3.3. Role of caveolae and caveolin-1 in the β2-AR-mediated relaxant response in mouse 
pulmonary artery   
To examine the role of caveolae in the β2-adrenergic-dependent relaxation, pulmonary 
arteries were incubated in the presence of methyl-β-cyclodextrin, a cholesterol-depleting 
agent that disrupts caveolae [21,22]. As shown in Figure 4, methyl-β-cyclodextrin treatment 
resulted in a 50% reduction of the procaterol-induced relaxation but had no significant effect 
on the endothelium-dependent relaxation to acetylcholine. 
The role of caveolin-1, an essential structural protein of endothelial caveolae, was further 
addressed in pulmonary arteries isolated from Cav-1 KO mice. The loss of caveolin-1 protein 
expression in Cav-1 KO pulmonary arteries (Fig. 5A) was associated with a disruption of 
caveolae at the endothelial cell membranes (Fig. 5B). As illustrated in Figure 5C, the 
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relaxation to procaterol was amplified and sustained in duration in Cav-1 KO compared to 
WT pulmonary arteries. On average, Cav-1 gene disruption increased the relaxant effect to 
procaterol by 179% in area (Fig. 5D) and 39% in amplitude (Fig. 5E) compared to WT 
pulmonary arteries. By contrast, the relaxant response to acetylcholine was similar in terms of 
amplitude and duration in WT and Cav-1 KO pulmonary arteries (Fig. 5D & E). As in WT 
mice pulmonary arteries, both procaterol and acetylcholine-induced relaxations were 
markedly decreased by L-NAME, a NOS inhibitor, in Cav-1 KO mice pulmonary arteries 
(Fig. 5E). Furthermore, we have observed that PTX treatment significantly decreased the 
relaxation to procaterol in Cav-1 KO mice pulmonary arteries [63.8±4.6% relaxation in 
control arteries (n=6) compared to 39.5±8.2% in PTX-treated arteries (n=6); P<0.05; data not 
shown]. Altogether, these results suggest that the β2-AR coupling to Gi/o protein is preserved 
in the absence of Cav-1 and that caveolin-1 exerts a negative control on the β2-adrenergic 
relaxant pathway.  
Src-kinase is known to phosphorylate caveolin-1 at Tyr14 [23]. We therefore investigated 
the effect of β2-AR stimulation on caveolin-1 phosphorylation at this residue. Incubation of 
pulmonary arteries with procaterol caused a transient increase in caveolin-1 phosphorylation 
at Tyr14 which was clearly seen at 30 sec- (Fig. 6) but disappeared at 5 min-incubation (data 
not shown). The level of caveolin-1 phosphorylation induced by a 30 sec-stimulation with 
procaterol was decreased by more than 50% not only in the presence of PP2, the Src-kinase 
inhibitor, but also in PTX-pretreated arteries (Fig. 6). 
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4. Discussion 
 
Endothelial β2-AR stimulation elicits a NO-dependent relaxant response in both systemic 
[7-9] and pulmonary [6] vasculature. However, the molecular mechanisms involved in the 
coupling of β2-ARs to eNOS activation remained poorly understood. The present study 
depicts accurately the signaling cascade of the mouse pulmonary β2-AR. We report that the 
endothelial β2-adrenergic-mediated pulmonary relaxation involves a Gi/o protein/Src-
kinase/PI3K/Akt pathway responsible for eNOS activation through its phosphorylation at the 
Ser1177 residue. Interestingly, our results provide evidence for a tight control of this pathway 
by caveolin-1. 
 
Historically, β2-ARs were classified as Gs-protein coupled receptors. However, it is now 
widely recognized that β2-ARs can also efficiently couple to Gi/o proteins. Our previous study 
demonstrated that the relaxation induced by β2-AR stimulation in mouse pulmonary artery is 
independent of the cAMP/PKA pathway [6], which strongly argues against the involvement 
of Gs proteins. In this study, we found that the mouse pulmonary β2-adrenergic vasorelaxant 
response was decreased by PTX, which is known to ADP-ribosylate Gi/o proteins in arterial 
preparations [24]. The fact that PTX failed to alter the relaxant response to the muscarinic 
agonist acetylcholine, which likely involves activation of Gq proteins, confirmed the 
specificity of PTX in our experimental conditions. Our results indicate that mouse pulmonary 
endothelial β2-AR couples to Gi/o proteins to trigger the signaling cascade involved in NO-
dependent relaxation. PTX treatment decreased the β2-adrenergic response by only 50%. This 
might be explained either by the partial inhibition of Gi/o proteins in our experimental 
conditions, or by the contribution of other G proteins in the β2-adrenergic vasorelaxant 
response. However, such a coupling of β2-ARs to Gi/o proteins might be the standard coupling 
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in endothelial cells as it has also been recently reported in human umbilical vein endothelial 
cells (HUVEC) [25] and in rat carotid artery [16]. 
 
Phosphorylation of eNOS at the Ser1177 residue is now recognized as a major mechanism of 
eNOS activation following diverse stimuli such as shear stress or receptor agonists [26]. 
However, the effect of endothelial β2-AR stimulation on eNOS phosphorylation state has been 
little studied. In rat aorta and cultured HUVEC, β2-AR stimulation has been reported to 
increase the phosphorylation of eNOS at the Ser1177 in a PKA- and PI3K/Akt-dependent 
manner [9,25]. In this study, we found that in mouse pulmonary artery, β2-AR activation 
promoted the phosphorylation of eNOS at the Ser1177, with kinetics consistent with the 
resulting vasorelaxation. We also demonstrated that PTX, Src kinase inhibitor and Akt 
inhibitor not only abolished the β2-adrenergic-mediated eNOS phosphorylation on Ser1177, but 
also reduced the vasorelaxant response related to the β2-AR stimulation. By contrast, 
inhibitors of ERK1/2, p38-MAPK, JNK and AMPK (present study), and also of the 
cAMP/PKA pathway [6], did not modify the β2-adrenergic response. Taken together, these 
results indicate that in mouse pulmonary artery, the β2-adrenergic relaxant response partly 
involves eNOS phosphorylation at Ser1177 through a Gi/o proteins-, Src kinase- and PI3K/Akt-
dependent, but cAMP/PKA-, MAPK- and AMPK-independent pathway. Such a β2-AR 
coupling to the PI3K/Akt pathway [9,27,28] or to the Src kinase pathway [16,29] has been 
previously reported to participate in the β2-AR signaling in different cell types, including 
endothelial cells. However, in this study we show for the first time that both pathways 
contribute together to the β2-AR triggered eNOS phosphorylation and subsequent 
vasorelaxation. Our data suggest that, upon β2-AR activation, Akt is the kinase which directly 
phosphorylates eNOS at Ser1177, as widely recognized in different cell types [26], whereas the 
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Src tyrosine kinase likely acts upstream of PI3K/Akt, as clearly described in the endothelial 
estrogen receptor signaling cascade [19,30].  
The fact that PTX, Src kinase inhibitor and Akt inhibitor abolished the β2-adrenergic effect 
on eNOS phosphorylation at Ser1177, but only partly reduced its vasorelaxant response, 
whereas this β2-adrenergic relaxant response has been shown to be totally eNOS-dependent 
[6], suggests that other mechanism(s) than eNOS phosphorylation at Ser1177 are involved in 
eNOS activation triggered by β2-AR stimulation in mouse pulmonary artery. Interestingly, we 
have shown that Src kinase and Akt inhibitors exert additive inhibitory effects on the β2-
adrenergic relaxant response. Furthermore, Src kinase is known to exert a striking role in 
eNOS-dependent signaling related to its ability to directly phosphorylate caveolin-1 at Tyr14 
[23] and Src kinase-dependent phosphorylation of caveolin-1 has recently been proposed to 
promote caveolin-1 dissociation from eNOS, leading to eNOS activation and caveolae-
mediated endocytosis [31,32]. In this context, we focused on the potential role of caveolin-1 
in the additional mechanism responsible for β2-AR-dependent eNOS activation. Here, we 
reported for the first time that β2-AR stimulation induced a rapid and transient increase in 
caveolin-1 phosphorylation at Tyr14, which was reduced by PTX or Src kinase inhibitor. Thus, 
this suggests that in mouse pulmonary artery, the Gi/o proteins/Src kinase pathway contributes 
to eNOS activation not only through its phosphorylation at Ser1177, but also through a 
caveolae-dependent mechanism. As the inhibitory effect of PTX and PP2 was only partial on 
the β2-AR-mediated caveolin-1 phosphorylation but total on the β2-AR-mediated eNOS 
phosphorylation, we can not exclude that another signaling pathway contributes to the 
increased caveolin-1 phosphorylation. This would deserve further investigation.  
 
We therefore provided additional evidence for a role of caveolin-1 in the mouse pulmonary 
β2-AR-elicited relaxant response by using two different models of caveolae disruption. 
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Pharmacological disruption of caveolae by methyl-β-cyclodextrin, a cholesterol-binding agent 
[21], decreased the β2-AR-mediated relaxant response, whereas the genetic disruption of 
caveolae, by using arteries isolated from Cav-1 KO mice, increased the β2-AR response, 
which was still Gi/o proteins-dependent, as shown by its inhibition in arteries treated with 
PTX, and eNOS-dependent, as shown by its abolition in the presence of the NOS inhibitor L-
NAME. The apparent discrepancy in the vascular functional consequence of pharmacological 
or genetic caveolae disruption has been recently discussed [33]. According to these authors, 
caveolin-1 protein expression persists after methyl-β-cyclodextrin treatment, and acts as a 
scavenger of eNOS protein, inhibiting its activity, whereas in Cav-1 KO arteries, eNOS 
protein becomes free and more active. Our results are consistent with - and further support - 
this model, as it is the first time, to our knowledge, that the effect of both pharmacological 
and genetic disruptions was investigated in parallel on a NO-dependent vasorelaxation in a 
given artery. This point is important because vasorelaxant responses studied in arteries 
isolated from Cav-1 KO mice have been shown to be decreased, increased or not modified, 
depending on the vasorelaxant agent or the vascular bed studied [32,34-36]. Regarding the β2-
AR-mediated vasorelaxation, Neidhold et al. reported that it was not modified in the 
saphenous artery from Cav-1 KO mouse [37]. However, the contribution of the endothelium 
to this relaxant response was not investigated and the authors assumed it to be smooth 
muscle-dependent. Thus, a major finding of our study is that endothelial caveolin-1 plays a 
key role in controlling the β2-AR-dependent activation of eNOS in mouse pulmonary artery, 
but is not required for β2-AR coupling to Gi/o proteins. Even if we can not conclude about the 
localization of β2-ARs in the pulmonary endothelial caveolae, the latter appear to be non-
essential structures in the β2-AR signaling pathway, as suggested by data obtained in Cav-1 
KO mice. 
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Contrary to the β2-AR-mediated response, the muscarinic receptor-mediated relaxation of 
mouse pulmonary arteries, which is also fully NO-dependent, was not affected by either 
pharmacological or genetic disruptions of endothelial caveolae. Acetylcholine-induced 
relaxation has been shown to be decreased after membrane cholesterol depletion in different 
rat arteries [38,39], but either increased or not modified in systemic arteries isolated from 
Cav-1 KO mice [34,36,37]. These differences are currently unexplained. Our results highlight 
the fact that the role of caveolae in NO-dependent relaxant responses may vary from one 
vascular bed to another. They also suggest that in mouse pulmonary artery, the endothelial 
muscarinic receptor regulates a pool of eNOS which is not necessarily controlled by caveolin-
1. 
 
5. Conclusions 
 
To conclude, our current study indicates that the mouse pulmonary endothelial β2-AR is 
coupled to a Gi/o-Src kinase-PI3K/Akt pathway to promote eNOS phosphorylation at Ser1177 
leading to a NO-dependent vasorelaxation, and that caveolin-1 exerts a negative control on 
this response, which is removed by its phosphorylation at Tyr14 through a Gi/o-Src kinase 
pathway (Fig. 7). In addition, our data clearly show that the mouse pulmonary endothelial β2- 
and muscarinic-receptors activate eNOS through distinct signaling pathways, which differ 
especially in their dependence on caveolin-1. This further supports the concept that 
mechanisms underlying eNOS activation are key determinants of pulmonary endothelial 
dysfunction and may explain why, unlike the muscarinic relaxation, the β2-adrenergic 
relaxation is preserved in pulmonary arteries isolated from mice subjected to chronic hypoxia 
[6]. 
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Legends for figures 
 
Figure 1:  Role of Gi/o proteins in the β2-AR-mediated relaxant response in mouse pulmonary 
artery. The relaxant responses to 0.1 µM procaterol and 10 µM acetylcholine were evaluated 
in arteries precontracted with PGF2α, which were pre-incubated in the absence or presence of 
PTX (400 ng/ml for 12 hours). A: Representative traces of wall tension recording showing the 
relaxant effect of procaterol in pulmonary arteries pretreated in the absence (Control) or 
presence of PTX (+PTX). B: Relaxations induced by procaterol and acetylcholine are 
expressed as a percentage of PGF2α-induced contraction. Data are mean ± SEM of 8 
experiments. * P<0.05 versus control. 
 
Figure 2: Role of PI3K/Akt pathway and Src-kinase in the β2-AR-mediated relaxant response 
in mouse pulmonary artery. The relaxant response to 0.1 µM procaterol was evaluated in 
arteries precontracted with PGF2α, in the absence or presence of inhibitors of PI3K (0.1 µM 
wortmannin or 10 µM LY 294002), Akt (5 µM Akt inhibitor X), Src-kinase (10 µM PP2), or 
MAPK (10 µM UO126, 20 µM PD 98059, 5 µM SB 203580 or 10 µM SP 600125) or AMPK 
(2 µM compound C). A-C: Representative traces of wall tension recording showing the 
relaxant effect of procaterol in pulmonary arteries pretreated in the presence of vehicle 
(DMSO; A), wortmannin (B) and U0126 (C). D&E: Relaxations induced by procaterol in the 
absence (procaterol) or presence of the different kinase inhibitors (D: wortmannin, LY 
294002, Akt inhibitor X or PP2; E: UO126, PD 98059, SB 203580, SP 600125, or compound 
C) are expressed as a percentage of PGF2α-induced contraction. Data are mean ± SEM of 3-7 
experiments. * P<0.05; ** P<0.01; *** P<0.001 versus procaterol alone. 
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Figure 3: β2-AR-stimulation induces eNOS phosphorylation through Gi/o proteins, PI3K/Akt 
and Src-kinase pathways in mouse pulmonary arteries. Western blot analysis for phospho-
eNOS (Ser1177) and total eNOS proteins was performed on arteries incubated with 0.1 µM 
procaterol (Procaterol) or not (Control). A: Effect of 30 sec and 5 min incubation times with 
procaterol. Top, representative blots. Bottom, densitometric ratios of phospho-eNOS 
(Ser1177)/eNOS bands, expressed as mean ± SEM of 3 experiments. § P<0.05 versus control. 
B: Effect of a 5 min-incubation with procaterol in the absence or presence of Akt inhibitor X 
(5 µM) or PP2 (10 µM, a Src-kinase inhibitor) or in arteries pretreated or not with PTX (400 
ng/ml for 12 hours). Top, representative blots. Bottom, densitometric ratios of phospho-eNOS 
(Ser1177)/eNOS bands are expressed as mean ± SEM of 3-5 experiments. § P<0.05 versus 
control. * P<0.05 versus procaterol alone. 
 
Figure 4: Role of membrane cholesterol in the β2-AR-mediated relaxant response in mouse 
pulmonary artery. The relaxant responses to 0.1 µM procaterol and 10 µM acetylcholine were 
evaluated in arteries precontracted with PGF2α, in the absence (Control) or presence of 1 mM 
methyl-β-cyclodextrin (+ methyl-β-cyclodextrin). A: Representative traces of wall tension 
recording showing the relaxant effect of procaterol in pulmonary arteries pretreated in the 
absence or presence of methyl-β-cyclodextrin. B: Relaxations induced by procaterol and 
acetylcholine are expressed as a percentage of PGF2α-induced contraction. Data are mean ± 
SEM of 4 experiments. * P<0.05 versus control. 
 
Figure 5: Role of caveolin-1 in the β2-AR-mediated relaxant response in mouse pulmonary 
arteries. 
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A: Expression of caveolin-1 protein (Cav-1) assessed by Western blot in homogenates from 
pulmonary arteries isolated from WT and Cav-1 KO mice. Blots shown are representative of 
3 experiments. β-actin was used as a loading control. 
B: Representative transmission electron micrographs performed in pulmonary arteries from 
WT and Cav-1 KO mice. Arrows indicate the presence of caveolae (defined as 50-100 nm 
round-shaped membrane invaginations) at the endothelial cell membrane. Original 
magnification at x 60 000 (with further magnification in insets). Photos are representative of 
experiments performed on 3 WT and 3 Cav-1 KO mice. 
C: Representative trace of wall tension recording in pulmonary arteries isolated from WT and 
Cav-1 KO mice showing the relaxant effect of 0.1 µM procaterol after PGF2α-induced 
contraction. The hatched area corresponds to the area of the relaxant effect of procaterol 
which is quantified in panel D. 
D: Area of the relaxant effect of 0.1 µM procaterol (hatched area in panel C) and 10 µM 
acetylcholine in pulmonary arteries isolated from WT and Cav-1 KO mice and precontracted 
with PGF2α. Results (in arbitrary units, a.u.) are expressed as area of relaxation reported to the 
amplitude of contraction induced by PGF2α. Data are mean ± SEM of 6 to 8 experiments. # 
P<0.05 versus WT mice. 
E: Relaxant effect to 0.1 µM procaterol and 10 µM acetylcholine in pulmonary arteries 
isolated from WT and Cav-1 KO mice, in the absence (Control) or presence (+ L-NAME) of 
300 µM L-NAME. Results are expressed as a percentage of PGF2α-induced contraction. Data 
are mean ± SEM of 4 to 8 experiments. *** P<0.001 versus control. # P<0.05 versus WT mice. 
 
Figure 6: Role of Gi/o proteins and Src-kinase pathway in the β2-AR-mediated 
phosphorylation of caveolin-1 at Tyr14 in mouse pulmonary arteries. Western blot analysis for 
phospho-caveolin-1 (Tyr14) and total caveolin-1 proteins was performed in control arteries 
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(Control) and arteries incubated with 0.1 µM procaterol for 30 sec (Procaterol) in the absence 
or presence of PP2 (10 µM) or arteries pretreated with PTX (400 ng/ml for 12 hours). Top, 
representative blots. Bottom, densitometric ratios of phospho-caveolin-1 (Tyr14)/caveolin-1 
bands are expressed as mean ± SEM of 4 experiments. §§§ P<0.001 versus control. * P<0.05 
versus procaterol alone. 
 
Figure 7: Schematic representation of the proposed signaling pathway responsible for eNOS-
dependent β2-AR-mediated vasorelaxation in mouse pulmonary artery. Left, In endothelial 
cell, caveolin-1 (Cav-1) maintains eNOS in its inactive state. Right, Upon β2-AR stimulation, 
the activated Gi/o/Src-kinase (Src K.) pathway elicits eNOS activation through two pathways: 
a direct phosphorylation of caveolin-1 at Tyr14 which dissociates eNOS from caveolin-1, and 
an indirect phosphorylation of eNOS at Ser1177 through a PI3K/Akt pathway. NO produced by 
activated eNOS induces relaxation of the smooth muscle cell, through a guanylate cyclase 
(GC)-cGMP-dependent pathway [6]. ERK1/2, p38MAPK, JNK and AMPK are not involved 
in the β2-adrenergic vasorelaxation. Note that the exact membrane localization of the β2-AR, 
in or outside the caveolae, remains unknown. Pharmacological agents used in experiments to 
inhibit the activity of different enzymes of the pathway are indicated in blue boxes.  
 
